1、The Annual Clinical Trials RoundupOctober 2024White PaperHeidi ChenAssociate Director,Research&Commercial Services2024 Edition:Promising Road to Recovery2October 2024 Copyright 2024 Citeline,a Norstella company.(Unauthorized photocopying prohibited).The Annual Clinical Trials Roundup1.The data snaps

2、hot dates for full-year activity are June 21,2024;June 26,2023;June 23,2022;June 14,2021;June 12,2020;June 5,2019;June 6,2018;and July 6,2017.Due to delays in reporting of trial activity,counts for prior years will have likely grown since the original data snapshot date.Welcome to the 2024 edition o

3、f Clinical Trials Roundup.Last year,we unveiled a landscape of increasing complexity,culminating in an unprecedented decline of clinical trial initiations.The biopharma industry weathered post-pandemic adjustments,endured economic hardships and slowed growth in major markets,met regulatory pressures

4、 to incorporate diversity,equity,and inclusion(DE&I),and suffered the impacts of geopolitical conflicts.Last year,we concluded with a cautiously optimistic outlook,anticipating the industrys imminent breakthrough in clinical trial innovation.Continuing with our annual tradition of Clinical Trials Ro

5、undup review,the 2024 analysis focuses on an overview of the Phase IIII clinical trials that initiated in the prior calendar year(2023)across all therapeutic areas(TAs)comprehensively covered by Trialtrove,as well as in-depth analyses into the key diseases,sponsoring companies,and geographies that i

6、mpact the pharmaceutical industry.We will survey the recovery in clinical trial activity that occurred as the pandemic gradually de-escalated to an endemic and how it reflects the current clinical landscape.As of June 21,2024,Trialtrove curated 9,959 Phase IIII clinical trials(Table 1)investigating